US drugmaker AbbVie has finally faced its D-Day, having had to deal with declining revenues from its inflammatory diseases drug Humira (adalimumab) due to the f 2 February 2024
OneChain Immunotherapeutics (OCI), a Spanish biotech focused on the development of CAR-T therapies for the treatment of oncologic diseases, has named Stefanos T 1 February 2024
French pharma major Sanofi was trading 4% lower late Thursday after presenting its fourth quarter and full year 2023 financial results. 1 February 2024
British drugmaker GSK has exceeded expectations in the fourth quarter, with chief executive Dame Emma Walmsley presenting an upbeat view of the company’s trajec 31 January 2024
Weaker-than-expected revenues from prostate cancer med Pluvicto (lutetium vipivotide tetraxetan) held back Swiss cancer giant Novartis in its latest financial r 31 January 2024
The US supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review for patients with un 29 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.